Biomea Fusion To Present Phase 1 Clinical Results For BMF-650, Investigational Next-Gen Oral Small Molecule GLP-1 Receptor Agonist, At ObesityWeek 2026

Benzinga · 2d ago

Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek® 2026. The conference will take place November 14–17, 2026, at the Gaylord National Resort & Convention Center in National Harbor, Maryland.